However, I can provide a on the topic of Pharmaceutical Biotechnology . You can copy this text directly into a Word document and save it as a PDF for your reference.
Traditional pharmaceuticals are small, chemically stable, and often taken orally. Biotech drugs (biologics) are massive proteins that cannot survive stomach acid and must be injected. While small molecules diffuse throughout the body, biologics are highly specific, reducing off-target side effects. For example, statins (small molecules) lower cholesterol broadly, whereas PCSK9 inhibitors (monoclonal antibodies) target a single protein in the liver with extreme precision.
Biologics pose unique regulatory hurdles. The FDA’s Center for Biologics Evaluation and Research (CBER) oversees these products. Unlike generic small molecules, there is no such thing as a true "generic biologic"; instead, we have biosimilars , which are highly similar but not identical due to the inherent variability of living systems.
Monoclonal antibody (mAb) technology represents another pillar. These Y-shaped proteins are designed to bind to specific antigens (e.g., cancer cell markers). By attaching toxins or immune activators to these antibodies, biotechnologists created "guided missiles" like Rituximab (for lymphoma) and Trastuzumab (for breast cancer), which kill malignant cells while sparing healthy tissue.
The backbone of pharmaceutical biotechnology lies in recombinant DNA (rDNA) technology. Before 1982, human insulin was extracted from pigs and cattle, leading to allergic reactions and supply issues. With rDNA, scientists inserted the human insulin gene into E. coli bacteria, turning them into microscopic factories. This breakthrough paved the way for other recombinant proteins, including human growth hormone (hGH), erythropoietin (EPO) for anemia, and clotting factors for hemophilia.
